Scarcity is a program the cell runs, and it can be opened without scarcity.
Two of its three actions converge on that program — the sensor reporting low fuel (AMPK) and the deacetylase carrying out the response (SIRT1) — the same pair recruited by fasting and by caloric restriction. The third sits on the stress axis, where cortisol is regulated (HPA), and that is where the adaptogenic reputation comes from. It is taken daily and not acutely, because a program is held open, never tripped.
Holding a scarcity program open has consequences well past the sensor. Growth restraint is its other face; cellular cleanup and the clearance of worn-out cells are what the program is for; built mitochondria and mitochondrial energy are what it leaves behind. Insulin sensitivity, fasting insulin, blood-sugar handling, liver fat and weight move with it, while antioxidant defense, calmed inflammation, immune support and the stress-relapse axis cover the ground a daily tonic is actually taken for.
Three primary pathways of the seventeen it targets. A pathway opens only on graded, published evidence, shown with its source at the ingredient level.
Educational only. Not evaluated by the FDA.
The story of Gynostemma (Herb of Immortality)
Gynostemma — ‘The Herb of Immortality’ — for staying green in every season. In the mountains of southern China, a climbing vine grows along the edges of the forest, and the villages that brewed it gave it a name that sounds like an exaggeration: the herb of immortality. Names like that are usually where a story ends. Here it is where this one begins, because the vine turns out to speak directly to the machinery of long life. It speaks first to the fuel gauge (AMPK). Every cell carries a sensor that reads its energy reserves, and when the reading is low, it switches the cell from spending to conserving: burning fat, clearing sugar, calling off building it does not need. It is the same switch that exercise and fasting throw. Gynostemma throws it too, and the cell behaves as if it had been active and lean. It speaks next to the longevity switch (SIRT1), the enzyme that turns the body’s repair and maintenance programs on when times are lean, protecting DNA and tidying the cell from within. And it speaks to stress. The axis that floods the body with cortisol in a crisis (the HPA axis, cortisol) is meant to stand down afterwards. The vine belongs to the tradition of adaptogens, plants that help the body answer stress in proportion and then return to calm. It comes to you as the plant alone, leaf and vine, concentrated whole. Holding a scarcity program open has consequences well past the sensor. Growth restraint is its other face; cellular cleanup and cleared worn-out cells are what the program is actually for; built mitochondria are what it leaves behind. Insulin sensitivity, blood-sugar support and weight move with it. Antioxidant defense, calmed inflammation and immune support cover the ground a daily tonic is genuinely taken for — not a lift, but a floor that stops dropping. Evergreens do not avoid winter. They are built to come through it unchanged. Fuel managed, repair switched on, stress answered and released: that is the evergreen in you.
Gynostemma is an adaptogenic longevity tonic and an AMPK powerhouse. Triglycerides measured on top of the drug, not instead of it.
★ 5.0 · 200:1 · $99
The studies, finding by finding
22 randomized trials, 2,407 adults on lipid drugs: added on, triglycerides and LDL fell further and HDL rose.
A crossover trial with a washout between arms, which makes each person their own control and removes the differences between people entirely. Four weeks of the tea dropped fasting glucose 1.9 mmol/L against 0.2 on placebo tea, at P<0.001. The comparator was tea, not nothing.
Measured directly under a controlled glucose infusion, insulin resistance fell markedly.
Sixteen weeks against placebo, measured by DXA: body weight, BMI and fat mass all fell significantly.
Fasting glucose and resting leptin both fell in the same participants.
Twenty-four weeks against placebo. Hair elasticity rose 58.14 gf against 19.92 on placebo at p<0.0001, and density rose 14.04 hairs per square centimeter against 4.85. Two separate measurements, one of strength and one of count, both separating clearly from placebo over half a year.
In infected animals, 75 percent were alive at twenty-four hours on gypenosides, against 5 percent untreated.
Prevention: stone incidence ran 90 percent on the stone-forming diet and 20 percent with gypenosides.
After blood flow to the heart was cut and restored, gypenosides kept left-ventricular pressure significantly higher and shrank the area of dead tissue dramatically.
Under sustained strain, heart muscle cells enlarge before failure; gypenosides shrank them from 577 to 296 square micrometers, in clean steps.
Six weeks on an atherogenic diet: arterial lesions significantly reduced, with total cholesterol, LDL and triglycerides all falling alongside.
After a stroke-type injury: infarct size significantly smaller, brain swelling lower, and neurological severity scores improved.
Under an inflammatory challenge that impaired both movement tests and raised three inflammatory messengers, gynostemma recovered the behavior and lowered the messengers.
Behavioral despair fell from roughly 240 seconds to about 180 on gypenoside XVII, with a comparable fall on a second, independent task.
Chronic stress cut willingness to enter open space to 47.1 percent of normal; the extract brought it back to about 82 percent.
Weight gain fell dose-dependently, and the short-chain fatty acids that gut bacteria produce from fiber rose across the board — acetate, and the others alongside it.
Lowered liver fat, scarring, the fatty-liver score, liver cholesterol and the collagen marker together.
What reaches the blood is not what was swallowed — it is what the body makes of it, and these metabolites were more active than the parent compound.
In cell work, its effect strengthened with exposure time, and cell migration and invasion fell in step.
These grades describe the maturity of the published science for each ingredient — not a claim that the product treats, cures, or is clinically proven for any goal. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.